财务数据和关键指标变化 - 公司第一季度收入增长21%,达到51.1百万美元,主要得益于手术套件数量的增加以及新技术的采用 [9][34] - 毛利率为80.2%,较上年同期下降0.7个百分点,主要由于产品组合的变化以及较低的专利费率 [36] - 经调整EBITDA亏损为8.3百万美元,较上年同期改善18% [38] - 公司现金、现金等价物和投资总额为112.1百万美元,有充足的资金支持战略投资和增长计划 [39] 各条业务线数据和关键指标变化 - 公司的Lapiplasty、Adductoplasty和相关手术量同比有所增长 [14] - 新产品如SpeedPlate、Hammertoe系统和无菌手术器械的采用率提高,带动了产品组合的改善 [14][15] 各个市场数据和关键指标变化 - 公司在第四季度的强劲表现延续至第一季度,带动了第一季度的业绩增长 [35] 公司战略和发展方向及行业竞争 - 公司正在从专注于Lapiplasty的公司向全面的脚趾畸形解决方案公司转型 [24][27] - 公司计划在2024年底推出两款创新的3D微创骨切术系统,以覆盖占整体手术量70%的第一跖骨骨切术市场 [24][25][26] - 公司面临来自微创骨切术解决方案和Lapiplasty仿制品的竞争压力,导致了收入指引的下调 [21][22][23] - 公司将采取措施保护知识产权,并通过成本控制来应对收入增长放缓 [31][82][83] 管理层对经营环境和未来前景的评论 - 管理层认为,尽管面临一些短期的竞争压力,但公司有信心通过推出新的3D微创骨切术解决方案来抓住未来的增长机会 [26][27][28][29] - 公司将继续专注于创新,并利用在Lapiplasty领域的领先地位来进军更大的骨切术市场 [27][28] 问答环节重要的提问和回答 问题1 **Lily 提问** 提问的内容:公司面临的竞争态势发生了什么变化,以及公司如何有信心重新夺回市场份额? [46][47] **John Treace 回答** 回答的内容:公司面临来自微创骨切术解决方案和Lapiplasty仿制品的竞争压力,导致了短期的业务增长放缓。但公司有信心通过推出自身的3D微创骨切术解决方案,以及持续创新和教育来重新夺回市场份额。[48][49][50][51][52] 问题2 **Drew Ranieri 提问** 提问的内容:公司是否可以就收入指引的下调提供更多细节,比如是否是由于手术量下降、平均售价下降还是其他因素? [70][71] **Mark Hair 回答** 回答的内容:公司预计未来仍将看到手术量和平均售价的增长,但由于面临的竞争压力,增速会有所放缓。公司将通过新产品的推出以及成本控制来应对这一局面。[72][73][74][75] 问题3 **Harrison Parsons 提问** 提问的内容:公司在成本控制方面有哪些具体措施? [82][83] **Mark Hair 回答** 回答的内容:公司将从可变成本如销售和营销费用等方面进行成本削减,同时也会在其他方面如管理费用和研发费用等方面进行适当的控制,以保持盈利能力。公司有足够的灵活性来有效管理整体成本结构。[83][84][85]

"333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (Stat ...

Exhibit 99.1 Treace Medical Concepts Reports First Quarter 2024 Financial Results PONTE VEDRA, Fla. – May 7, 2024 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Revenue of $51.1 million in first ...

Treace Medical Concepts Inc (NASDAQ:TMCI) Q4 2023 Results Conference Call February 27, 2024 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - CEO, Founder & Director Mark Hair - Chief Financial Officer Conference Call Participants Drew Ranieri - Morgan Stanley Robbie Marcus - JPMorgan Rick Wise - Stifel Simon Nigan - UBS Richard Newitter - Truist Securities Ryan Zimmerman - BTIG George Sellers - Stephens Operator Good day, and thank you for standin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-40355 TREACE MEDICAL CONCEPTS, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-1052 ...

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Lilia-Celine Lozada - JPMorgan Richard Newitter - Truist Securities Rick Wise - Stifel Andrew Ranieri - Morgan Stanley Ryan Zimmerman - BTIG George Sellers - Stephens Inc. Operator Good day and ...

or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (State ...

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Lilia-Celine Breton Lozada - JPMorgan Ryan Zimmerman - BTIG Operator Good day and thank you for standing by. Welcome to the Treace Medical Concepts' Second Quarter 2023 Earnings Conference Call. At this time, all participa ...

“333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (State ...

“333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (Stat ...